The form AMYCOR 1 PER CENT is adapted to the local treatment of mycoses, cutaneo-mucosa

· Large folds and small folds, in particular, associated with maceration

Candidoses

The candidiasis encountered in human clinical is usually due to Candida albicans. However, the demonstration of a Candida on the skin can not in itself be an indication.

Treatment of intertrigos

· Genital-crural, anal and perianal

· Submammary

· Interdigital.

In some cases, it is recommended to treat the digestive tract simultaneously.

Dermatophyties

· Treatment of genital and crural intertrigos.

· Treatment of toe intertrigos (athlete's foot), prophylaxis of relapses

AMYCOR powder will be applied once a day, morning or evening, afterwards, toilet and drying of the skin. The duration of treatment depends on infectious organisms and sites of infection

Generally

· 3 weeks for dermatophytoses

· 2 to 3 weeks for candidiasis

· In the prophylaxis of relapses (foot of athletes, intertrigos interorteils): 1 application per day on the feet and in shoes for 6 months. >
Pharmacotherapeutic class

ANTIFONGIC FOR TOPICAL USE (DERMATOLOGICAL DRUGS)

ATC CODE: D01AC10

Antimycotic imidazole, bifonazole has a broad spectrum including dermatophytes, yeasts, molds, certain fungi (Malassezia furfur) and gram + bacteria such as corynebacterium and staphylococcus. The activity of bifonazole is fungicidal in vitro on dermatophytes, above the concentration of 5μg / ml. In vitro tests did not demonstrate acquired resistance

The hygroscopic power of rice starch is opposed to maceration.

Hypersensitivity to an antimycotic agent of the imidazole group or to a component of the powder

Warnings

In spite of the available clinical data, which is reassuring, in this case, and a weak transcutaneous passage, it is advisable to note the experimental toxicity of this active substance administered by general route in several animal species. >

· The emergence of systemic effects is unlikely due to the very low rate of resorption in healthy skin. However, on wounded skin, on a large surface or in the infant (due to the surface / weight ratio and the occlusion effect of the layers), caution is required.
< Br>

Precautions for use

In certain cases, and especially in mycoses of the peri-buccal and peri-anogenital sphere, it is recommended to treat the digestive tract simultaneously.

The data available to date do not imply the existence of clinically significant interactions.

No case of overdose has been reported. However, a possible overdose may lead to an exacerbation of undesirable effects.

Pregnancy

Although no teratogenic effects have been observed in animal studies, this product should not be administered during the first trimester of pregnancy. >

Some signs of local irritation (pruritus, burning, erythema) and dyshidrosis have been reported, most often moderate and transient, and they cease spontaneously upon discontinuation of treatment.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorization of the drug is important. It permits continuous monitoring of the benefit / risk ratio of the drug. Health professionals must report any adverse reactions suspected through the national reporting system: National Agency for the Safety of Medicines and Health Products (Ansm) and Network of Regional Centers for Pharmacovigilance. Ansm.sante.fr.

The form AMYCOR 1 PER CENT is suitable for the local treatment of mycoses, mucous membranes, large folds and small folds, more particularly associated with maceration Candidoses The candidiasis encountered in human clinical are usually due to Candida, albicans. However, the demonstration of a Candida on the skin can not in itself be an indication.Treatment of intertrigos, • genital-crural, anal and perianal, • submammary, • interdigital. It is advisable to treat the digestive tract simultaneously Dermatophyties Treatment of genital and crural intertrigos Treatment of toe intertrigos (athlete's foot) prophylaxis of relapses